Resumen de New Drug for Squamous Non–Small Cell Lung Cancer

Diane S. Aschenbrenner

• * Necitumumab (Portrazza) is a new epidermal growth factor receptor antagonist approved to treat advanced squamous non–small cell lung cancer in patients who haven't received medication for advanced lung cancer.

  * Risks include cardiac arrest and hypomagnesemia. The latter is extremely common. Electrolyte levels should be monitored closely.